Cross-border teams from Sullivan & Cromwell and Latham & Watkins have landed the lead roles on the $40bn takeover of Allergan’s generic-making business by Teva that has seen the Israeli pharmaceutical powerhouse also abandon its bid for Mylan.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact jasmine.glass@legalbusiness.co.uk
